Form 4: Acumen Pharma Grants Equity to Chief Legal Officer

Acumen Pharmaceuticals, Inc. granted 99,133 restricted stock units and 148,700 stock options to Chief Legal Officer Derek M. Meisner as part of his compensation.

Summary

• Derek M. Meisner, Chief Legal Officer & Corporate Secretary of Acumen Pharmaceuticals, Inc. (ABOS), reported new equity grants.
• Received 99,133 Restricted Stock Units (RSUs) on January 16, 2026, at a price of $0.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• RSUs will vest in three equal annual installments, commencing one year after the grant date, contingent on continuous service.
• Received 148,700 Employee Stock Options on January 16, 2026, with an exercise price of $1.89.
• Options will vest in 48 equal monthly installments, fully vesting on the fourth anniversary of the grant date, contingent on continuous service.
• The options have an expiration date of January 16, 2036.
• Following these transactions, Meisner beneficially owns 182,933 shares of Common Stock and 148,700 derivative securities (options).

Sentiment

Score: 6

Explanation: Slightly positive. While routine, equity grants for key executives are generally viewed positively as they align management's interests with shareholders and aid in retention. The potential for future dilution is a minor negative but expected with such compensation.

Positives

• Equity grants align the interests of the Chief Legal Officer with shareholders, incentivizing long-term performance.
• The vesting schedules for both RSUs and stock options promote executive retention over several years.

Negatives

• Potential future dilution for existing shareholders as RSUs vest and options are exercised.

Future Outlook

The vesting schedules for the granted RSUs and stock options indicate a commitment to retaining Derek M. Meisner, with awards vesting over three to four years, contingent on his continuous service to the company.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This grant aligns with typical industry practices for executive compensation packages.

Comparison to Industry Standards

• The use of RSUs and stock options for executive compensation is a common practice across the biotech and pharma sectors, similar to companies like Biogen or Moderna, which frequently utilize such instruments to align executive interests with long-term shareholder value.
• The vesting schedules (3 years for RSUs, 4 years for options) are within the typical range observed for executive equity grants in growth-oriented companies, aiming for sustained performance and retention.

Stakeholder Impact

• Shareholders: Potential for future dilution upon RSU vesting and option exercise, but also benefit from increased management alignment and retention.
• Employees (specifically Derek M. Meisner): Enhanced compensation package and long-term incentive to remain with the company.

Next Steps

• Continued service of Derek M. Meisner to ensure vesting of RSUs and stock options.
• Periodic vesting of RSUs in three equal annual installments starting January 16, 2027.
• Monthly vesting of stock options over 48 months, fully vesting by January 16, 2030.

Key Dates

Keywords

Acumen Pharmaceuticals, ABOS, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Derek Meisner, Chief Legal Officer, Corporate Secretary